Daclatasvir: a team player rather than a prima donna in the treatment of hepatitis C

Gut. 2015 Jun;64(6):860-2. doi: 10.1136/gutjnl-2014-307958. Epub 2014 Sep 5.
No abstract available

Keywords: HCV; INTERFERON.

MeSH terms

  • Antiviral Agents / administration & dosage*
  • Benzazepines / administration & dosage
  • Carbamates
  • Drug Resistance, Viral
  • Drug Therapy, Combination
  • Genotype
  • Hepacivirus / drug effects
  • Hepatitis C, Chronic / drug therapy*
  • Hepatitis C, Chronic / genetics
  • Hepatitis C, Chronic / virology
  • Heterocyclic Compounds, 3-Ring / administration & dosage
  • Humans
  • Imidazoles / administration & dosage*
  • Indoles / administration & dosage
  • Protease Inhibitors / administration & dosage
  • Pyrrolidines
  • Simeprevir
  • Sofosbuvir
  • Sulfonamides / administration & dosage
  • Uridine Monophosphate / administration & dosage
  • Uridine Monophosphate / analogs & derivatives
  • Valine / analogs & derivatives
  • Viral Nonstructural Proteins / antagonists & inhibitors

Substances

  • 8-cyclohexyl-N-((dimethylamino)sulfonyl)-1,1a,2,12b-tetrahydro-11-methoxy-1a-((3-methyl-3,8-diazabicyclo(3.2.1)oct-8-yl)carbonyl)cycloprop(d)indolo(2,1-a)(2)benzazepine-5-carboxamide
  • Antiviral Agents
  • Benzazepines
  • Carbamates
  • Heterocyclic Compounds, 3-Ring
  • Imidazoles
  • Indoles
  • NS3 protein, hepatitis C virus
  • Protease Inhibitors
  • Pyrrolidines
  • Sulfonamides
  • Viral Nonstructural Proteins
  • Simeprevir
  • Uridine Monophosphate
  • Valine
  • daclatasvir
  • Sofosbuvir